INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pharming Group N.V. - PHAR

Core Viewpoint - Pharming Group N.V. is under investigation for potential securities fraud and unlawful business practices following a negative response from the FDA regarding its drug application for Joenja® [1][3] Group 1: FDA Response - On February 1, 2026, Pharming announced that the FDA issued a Complete Response Letter (CRL) for its supplemental New Drug Application (sNDA) for Joenja® [3] - The FDA raised concerns about potential underexposure in lower weight pediatric patients and requested additional pharmacokinetic data to reassess proposed pediatric doses [3] - The letter also highlighted issues with one of the analytical methods used for production batch testing, requiring further data and clarification [3] Group 2: Market Reaction - Following the FDA's announcement, Pharming's American Depositary Receipt (ADR) price dropped by $3.495, or 17.07%, closing at $16.975 per ADR on February 2, 2026 [3]